MACE SECURITIES INTERNATIONAL (NASDAQ: MACE)
ICTS International N.V. (NASDAQ:ICTS)
Markland Technologies, Inc. (OTCBB:MRKL)
Digital Recorders, Inc. (Nasdaq:TBUS)

For Immediate Release
August 2, 2004

Emerging Equities has added MACE, ICTS, MRKL, TBUS for 8/2/04 "WATCH LIST"

TORONTO, ON, August. 2, 2004

Hot stock watch – Full coverage available to premium members.
MACE SECURITIES INTERNATIONAL (NASDAQ: MACE)
ICTS International N.V. (NASDAQ:ICTS)
Markland Technologies, Inc. (OTCBB:MRKL)
Digital Recorders, Inc. (Nasdaq:TBUS)


Mace Announces Authorization of Stock Buy Back Plan of up to $3.0 Million Dollars of Its Common Stock and Announces Sale of NJ-Based Car Wash
2004-07-30 08:00 ET - News Release
MOUNT LAUREL, N. J. -- (Business Wire) -- July 30, 2004
Mace Security International, Inc. ("Mace")
(Nasdaq:MACE), a manufacturer of electronic surveillance and personal defense products and an owner and operator of car and truck wash facilities, today announced that its Board of Directors authorized a Stock Buy Back Plan to purchase shares of the Company's common stock up to a maximum value of $3.0 million. Purchases will be made in the open market, if and when management determines to effect purchases. Management may elect not to make purchases or make purchases less than $3.0 million in amount.
At the current level of Mace's stock price and the resulting market capitalization, the Board of Directors consider Mace to be
undervalued. Mace's stock price is currently trading under its book value per share as of March 31, 2004 of $4.36.
The Company also announced that it signed a definitive agreement to sell an exterior-only car wash in southern New Jersey for
approximately $650,000. The selling price of the car wash is approximately $20,000 above its recorded book value. The decision to
sell this car wash was made as a result of receiving an offer that management thought was attractive given the marginal profit generated by the site. Mace Security International, Inc. is a manufacturer of electronic surveillance and personal defense products, and an owner and operator of car and truck wash facilities. Information about Mace is available at www.mace.com

HomelandDefenseStocks.com Reports: More Billions for Biodefense -- Are Vaccines the Answer?
2004-07-29 13:07 ET - News Release
www.HomelandDefenseStocks.com, (HDS) an investment news portal for the Homeland Defense and Security Sector, reports on treatments and vaccines in an exclusive featured article "More Billions for Biodefense -- Are vaccines the answer?" following the recent signing of Project BioShield into law by the President. Project BioShield, a $5.6 Billion bill that will stockpile new vaccines and develop countermeasures to bioterrorism attacks, will fuel demand for biological and chemical weapons detection and protection solutions. Within the biodefense community the question is being raised whether we should spend more on post-exposure treatments?
HDS does not make recommendations, but offers a unique, free information portal to investors to research news, articles, interviews and a growing list of participating public companies and featured profiled companies within the sector including: Aethlon Medical, Inc. (OTC BB: AEMD) and Markland Technologies, Inc. (OTC BB: MRKL).
More Billions for Biodefense -- Are vaccines the answer?
By Allen Gibson, HomelandDefenseStocks.com
With the recent signing by the President of the Project Bioshield Act of 2004, the federal government has authorized $5.6 Billion dollars in spending over the next ten years to increase American's security from biological attack.
Already, the government has purchased smallpox and anthrax vaccines -- 75 million doses in the case of anthrax -- as a key part of the Bioshield initiative. But is this a case of "fighting the last war" or defending against the last terror attack?
A report out of the University of Pittsburgh suggests that the life sciences are at the beginning of a revolutionary period. Scientific understanding of living systems and how to manipulate them is expanding exponentially. The report, from The Center for Biosecurity at the U of P, suggests our strategy should be "an ambitious and aggressive scientific research, development, and production (R & D & P) program that delivers the diagnostic technologies, medicines, and vaccines needed to counter the range of bioweapons agents."
...The doctors in charge of education for the National Center for Biodefense argue that less money should be spent on vaccine purchase and development, and more on post-exposure treatments.
Vaccines, say Drs. Ken Alibek and Charles Bailey, aren't going to be effective for civilian populations, since no one can know which specific agent to guard against, and the drugs must be administered in advance to be effective. Also, they say in a letter to the editor of the Biosecurity and Bioterror newsletter, it is far easier and takes fewer years to develop a weapons-grade disease than to produce a vaccine against it.
The immediate relevancy of programs other than vaccines was vividly demonstrated this July, when the FBI announced that Ricin compound was introduced into some baby food jars on the west coast. Minute amounts of Ricin can be fatal. The gaseous form of Ricin was used in the deadly Tokyo subway attacks a few years ago. And no vaccine or cure presently exists. Which means that new, non-vaccine; treatments are needed now, and will be needed in the future.
One example of how biotech can be repurposed to address the bioterror threat comes from Aethlon Medical (OTC BB: AEMD), who created a "Hemopurifier" machine to strip viruses and toxins out of the blood of infected patients. Originally designed to treat HIV and Hep C, the company is now working with the National Center for Biodefense at George Mason University to develop filtration devices that could be used by both the military and civilian populations against Class A bioterror agents. The Company will use new FDA rules to test the devices on animal species and extrapolate safety data for humans, since human tests are obviously not practicable.
Full article: www.HomelandDefenseStocks.com/Companies/HomelandDefense/Articles/Biodefense.asp

Emerging Equities currently offers this service to premium members. Join today and receive 50 “Hot Stock Watch” alerts per year.
Emerging Equities provides investors with featured stock picks and research reports. All stock picks are publicly traded on the Nasdaq, OTCBB, TSE, or TSX Venture Markets. Our focus is on short and long term prospects within a 1 to 6 month time frame. Majority of our researched stocks are under $1.00. All picks are research analyzed, and featured when a stock appears poised for growth...



Become an unlimited access Premium Member for only $7 per month! Visit www.ee.aslcapitalcorp.com for more info.

ASL Capital Corp website can be visited at www.aslcaptialcorp.com
Emerging Equities website can be visited at www.ee.aslcapitalcorp.com

Information contained herein is the opinion of Emerging Equities ("EE") and is intended to be used strictly for informational purposes. You should be aware that EE attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, EE does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of EE's analyses and/or parties related to those companies. EE also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC and/or OSC, BSC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.
EE, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a EE analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an EE opinion, recommendation or analysis. Information regarding companies which EE has opined upon is normally available from many sources including the subject company's filings with the SEC and/or OSC, BSC and various press releases issued by the company. You should be aware that EE is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating EE's statements regarding a company. EE has not been compensated for publication of this release. EE's officers and directors reserve the right to buy shares of the company discussed in this opinion and may profit in the event those shares rise in value. Emerging Equities is a division of ASL Capital Corp.
Contact: ASL Capital Corp 647.880.5400 sales@ee.aslcapitalcorp.com
SOURCE: www.ee.aslcapitalcorp.com




Emerging Equities currently offers this service to premium members. Join today and receive 50 “Hot Stock Watch” alerts per year.
Emerging Equities provides investors with featured stock picks and research reports. All stock picks are publicly traded on the Nasdaq, OTCBB, TSE, or TSX Venture Markets. Our focus is on short and long term prospects within a 1 to 6 month time frame. Majority of our researched stocks are under $1.00. All picks are research analyzed, and featured when a stock appears poised for growth...



Become an unlimited access Premium Member for only $7 per month! Visit www.ee.aslcapitalcorp.com for more info.

ASL Capital Corp website can be visited at www.aslcaptialcorp.com
Emerging Equities website can be visited at www.ee.aslcapitalcorp.com

Information contained herein is the opinion of Emerging Equities ("EE") and is intended to be used strictly for informational purposes. You should be aware that EE attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, EE does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of EE's analyses and/or parties related to those companies. EE also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC and/or OSC, BSC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.
EE, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a EE analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an EE opinion, recommendation or analysis. Information regarding companies which EE has opined upon is normally available from many sources including the subject company's filings with the SEC and/or OSC, BSC and various press releases issued by the company. You should be aware that EE is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating EE's statements regarding a company. EE has not been compensated for publication of this release. EE's officers and directors reserve the right to buy shares of the company discussed in this opinion and may profit in the event those shares rise in value. Emerging Equities is a division of ASL Capital Corp.
Contact: ASL Capital Corp 647.880.5400 sales@ee.aslcapitalcorp.com
SOURCE: www.ee.aslcapitalcorp.com